PPD (NASDAQ: PPD) is one of 35 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare PPD to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Insider and Institutional Ownership

51.1% of shares of all “Commercial physical research” companies are held by institutional investors. 17.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares PPD and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PPD $4.03 billion N/A 16.27
PPD Competitors $1.24 billion $44.58 million 8.97

PPD has higher revenue, but lower earnings than its peers. PPD is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares PPD and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PPD Competitors -123.36% -4.32% -3.12%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for PPD and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PPD 0 0 14 0 3.00
PPD Competitors 193 871 1648 80 2.58

PPD presently has a consensus price target of $32.46, suggesting a potential upside of 103.65%. As a group, “Commercial physical research” companies have a potential upside of 59.47%. Given PPD’s stronger consensus rating and higher probable upside, equities research analysts plainly believe PPD is more favorable than its peers.


PPD beats its peers on 8 of the 11 factors compared.

PPD Company Profile

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services. The Clinical Development Services segment provides product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The Laboratory Services segment offers bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. The company operates in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.